A healthcare AI proof-of-concept is a working software artifact that demonstrates whether a specific AI use case is technically feasible, clinically defensible, and economically attractive — built on real data, validated against real outcomes, and delivered in a structured time-box. The 6-week format is the operational sweet spot: long enough to ship an artifact that survives executive and clinician review, short enough to maintain decision-quality urgency. The week-by-week structure: Week 1 scopes the use case and confirms data access; Week 2 ships the data pipeline and the eval harness; Week 3 delivers the first model checkpoint; Week 4 runs the clinical accuracy review and refinement; Week 5 builds the demo experience and integration touchpoints; Week 6 produces the final artifact, the validation report, and the production-readiness assessment. Skipping any week produces a POC that fails one of the three readiness gates — technical, clinical, or economic.
The 6-week healthcare AI POC has become the operational standard at Taction Software® for the same reason 12-week MVPs and 6-month full builds have: the format works. It produces enough engineering throughput to ship something defensible while preserving the time-to-decision that distinguishes prototypes from production projects.
This guide is the week-by-week playbook drawn from the patterns we apply to every Discovery Sprint engagement. The format is reproducible. The artifacts are well-defined. The decision gates are non-negotiable. Buyers running their own internal POCs can apply the same structure; buyers engaging us run it as a productized $45K Discovery Sprint with the architectural foundation we ship as default.
What a Healthcare AI POC Has to Demonstrate
Before the week-by-week, the artifact requirements. A healthcare AI POC that survives the three readiness gates demonstrates four things.
Technical feasibility. The use case is buildable. The architecture has no fatal compliance gap, no impossible data-access requirement, no model-capability assumption that current frontier or open-source models can’t meet. The POC shows working code on real data producing recognizable output.
Clinical defensibility. The output meets a defensible accuracy bar against clinician gold standards. The eval harness reports the metrics that matter for the use case — sensitivity, specificity, calibration, decision-curve analysis where applicable, override rate where measurable. The output is not just plausible-sounding; it is correct at a measurable rate clinicians can defend.
Economic attractiveness. The use case has a defensible ROI case at projected scale. The unit economics work — per encounter, per clinician, per covered life, per case. The cost of building production substantially exceeds zero, and the POC has produced enough evidence to justify the production investment.
Production-readiness assessment. The POC includes an explicit assessment of what the gap is between POC and production — the engineering work, the compliance work, the integration work, the validation work. Production-readiness is rarely “the POC plus 30%.” It is usually 4–8x the POC engineering, with substantial new compliance and integration scope.
POCs that demonstrate three of the four typically pass executive review. POCs that demonstrate only two typically don’t. POCs that try to demonstrate all four superficially without delivering depth on any tend to fail all four review gates.
Pre-Week 1: The Scoping Conversation
Most failed healthcare AI POCs fail at the scoping conversation, not at the engineering. Before Week 1 starts, the project owner and the engineering team align on five questions.
Question 1 — What is the specific clinical or operational outcome the AI will affect? Not “improve clinician productivity” — specifically: reduce time-to-completed-discharge-summary by 50%; reduce 30-day readmission rate by 10%; reduce prior-auth letter drafting time by 70%. The outcome has to be measurable, attributable to the AI, and clinically meaningful.
Question 2 — What is the input data and where does it live? Specifically: the EHR (which one, accessed how), the claims system, the device feed, the unstructured documentation, the external data sources. The POC succeeds when data is accessible by Day 5; it fails when data access takes 4 weeks because no one confirmed availability before the engagement started.
Question 3 — What is the output format and where does it land? Specifically: a structured note written back to the EHR via FHIR DocumentReference; a probability score rendered in the encounter view; a draft letter with citations; a worklist priority signal. The output format determines the integration architecture.
Question 4 — Who is the user, and how do they consume the output? Specifically: an attending physician reviewing in Epic during the encounter; a coder reviewing in the institution’s coding workflow tool; a care manager reviewing in the population-health platform. The user determines the UX scope of the POC.
Question 5 — What is the regulatory and compliance posture? Specifically: does the use case cross into FDA SaMD territory; what is the data-residency requirement; what is the BAA scope; what is the audit-logging requirement. The compliance posture determines the architecture and the deployment path.
A POC kicked off with all five questions answered specifically ships in 6 weeks. A POC kicked off with vague answers — or wrong answers — typically misses the target by 4–8 weeks because the engineering work hits walls that the scoping should have surfaced.
Week 1: Scope, Data Confirmation, and Architecture
The week 1 deliverables are (1) a written scope document, (2) confirmed data access, (3) an architecture diagram that survives a compliance review, and (4) a kickoff with the clinical reviewer.
Scope document. A 2-page document specifying the use case, the input data, the output format, the user, the regulatory posture, the metrics that determine success, and the explicit out-of-scope boundaries. Out-of-scope matters more than people expect — the items the team explicitly will not handle in 6 weeks (production deployment, full EHR integration certification, multi-site validation, formal regulatory submission) get documented so executive review doesn’t reject the POC for failing to deliver scope it never agreed to.
Data access. By end of week 1, the team has hands on the data. For most engagements, this means a HIPAA-compliant data extract (de-identified where possible, or under BAA where not) loaded into a development environment. Synthetic data is acceptable for the first prototype iteration but real data has to land by end of week 2 for the POC to mean anything. Most POC failures trace back to data access blockers that weren’t flagged in week 1.
Architecture diagram. The end-to-end PHI flow map: where data enters, what transformations occur, what is sent to the model, what is returned, where the output lands. The architecture diagram has every PHI surface annotated with encryption, BAA coverage, retention policy, and logging policy. A POC architecture that doesn’t have a clean compliance story by end of week 1 is a POC that will hit a compliance wall in week 4.
Clinical reviewer kickoff. The clinician (or clinical informaticist) who will review POC output for accuracy is named and engaged. This is the single highest-leverage decision in the POC structure. POCs without a named clinical reviewer ship engineering output that nobody trusts. POCs with a strong clinical reviewer ship validated output that survives executive review on the strength of the reviewer’s signoff alone.
Decision gate. End of week 1: scope document signed off, data confirmed accessible, architecture reviewed for compliance, clinical reviewer engaged. Any gate failure stops the engagement until resolved — proceeding past a gate failure produces a POC that fails review in week 6.
Week 2: Data Pipeline and Eval Harness
The week 2 deliverables are (1) a working data pipeline that loads, processes, and exposes the input data, (2) the eval harness that will measure model output, and (3) a frozen test set the eval will run against.
Data pipeline. Code that reads the input data from its source (file extract, FHIR API, database query, message stream) and produces a clean dataset the model can consume. PHI handling is correct from day 1 — encryption, RBAC, audit logging at the pipeline level. The pipeline runs idempotently, handles errors, and supports running against test data and (eventually) production-shape data.
Eval harness. Code that computes the metrics the use case will be judged against. For a classification use case: sensitivity, specificity, AUROC with confidence intervals, calibration, Brier score. For a generation use case: factuality against gold-standard documents, citation accuracy, output structure validation, and clinician-rated quality scores. For a triage or routing use case: agreement with the gold-standard disposition, error-mode classification (under-triage vs. over-triage), subgroup performance.
The eval harness is the single most important artifact in the POC. It is what makes the POC defensible. POCs without rigorous eval methodology produce demo videos that look impressive and accuracy claims that fall apart under review. POCs with rigorous eval methodology produce metric tables that survive scrutiny.
Frozen test set. A held-out dataset the eval runs against. Frozen means it is locked from week 2 onward; no model iteration touches it. The size depends on the use case — typically 100–500 examples for generation use cases (clinician review is the bottleneck); 500–5,000 for classification or prediction use cases. The clinical reviewer reviews the test set in week 2 to confirm the gold-standard labels.
Decision gate. End of week 2: data pipeline runs against real data; eval harness runs end-to-end and produces a baseline metric (random or simple baseline); test set is frozen and clinician-reviewed.
Week 3: First Model Checkpoint
The week 3 deliverables are (1) the first end-to-end model run from input to output, (2) eval metrics computed against the frozen test set, and (3) the first iteration on prompts, retrieval, fine-tuning, or model selection based on the eval results.
End-to-end run. Model produces output for every example in the test set. Output is in the target format. Output flows through the data pipeline to the (mock) destination the user would consume from. This is the first integrated artifact of the POC.
Eval metrics on baseline model. The eval harness reports numbers. For most healthcare AI use cases, the first model checkpoint underperforms the eventual target — that is expected. The metrics establish the starting point.
First iteration. Based on eval results, the team makes the highest-leverage iteration. Common patterns:
- For RAG use cases — improve the retrieval layer; the model’s output quality is usually limited by what context it gets, not by the model’s reasoning.
- For prompt-engineered use cases — refine the prompt structure, add few-shot examples, change the output schema.
- For fine-tuned use cases — assess whether the base model is wrong (switch to a different base) or whether the fine-tuning data is insufficient (expand the corpus).
- For predictive ML use cases — feature engineering, label-quality review, hyperparameter sensitivity analysis.
Decision gate. End of week 3: model produces output end-to-end; eval metrics computed; first iteration applied. The metrics at end of week 3 forecast the metrics at end of week 6 — substantial gains in weeks 4–5 are common, but the trajectory is recognizable from week 3.
If the week 3 metrics are far below the target — say 50% of the success threshold — the engagement triggers a “go/no-go” conversation with the project owner. Going forward despite week 3 metrics that forecast failure typically produces a POC that disappoints in week 6. Acknowledging the gap in week 3 lets the team adjust scope (different use case, different data, different methodology) while there is still time to recover.
Week 4: Clinical Accuracy Review and Refinement
Week 4 is the highest-leverage week of the POC. The week 4 deliverables are (1) clinical reviewer signoff on a sample of model outputs, (2) error-mode analysis identifying systematic failure patterns, (3) targeted iterations addressing the highest-impact errors, and (4) updated eval metrics showing improvement.
Clinical reviewer signoff. The clinical reviewer rates a sample of model outputs against a defined rubric — accuracy, completeness, clinical safety, format. Quantitative ratings (1–5 scales on each dimension) are preferred to qualitative comments because they let the team measure improvement across iterations. Qualitative comments matter for error-mode identification but don’t substitute for quantitative scoring.
Error-mode analysis. The team categorizes the errors the model is making. For a documentation use case: hallucinated medication names, missed allergies, wrong negation handling, format errors, citation errors. For a prediction use case: false positives in specific subgroups, false negatives during specific time windows, calibration breaks at extremes. The categories drive the iteration priorities — addressing the highest-frequency error mode produces the largest accuracy gain.
Targeted iterations. The team applies the highest-leverage iteration based on the error-mode analysis. This is engineering work — better retrieval for hallucination errors, better prompt structure for format errors, additional training data for subgroup gaps, threshold tuning for calibration issues. Each iteration is run through the eval and compared against the previous metrics.
Updated eval metrics. The eval harness produces the post-iteration metrics. Week 4 typically delivers the largest single-week improvement of the POC because the iterations are now informed by clinical reviewer feedback rather than engineering intuition alone.
Decision gate. End of week 4: clinical reviewer has signed off on a representative sample at acceptable quality; error modes are characterized and prioritized; eval metrics show movement toward the target. If the metrics stalled or regressed in week 4, the team triggers another go/no-go conversation. Stalled improvement at week 4 typically forecasts a POC that doesn’t reach the target by week 6.
Week 5: Demo Experience and Integration Touchpoints
Week 5 transforms the working model into something that can be demonstrated to executives, clinical leadership, and operational stakeholders. The week 5 deliverables are (1) a demo experience showing the model in the user’s actual workflow context, (2) integration touchpoints simulating production data flow, and (3) an updated eval report packaged for non-technical review.
Demo experience. The model output rendered in the format and context the user would see in production. For an EHR-integrated copilot — a SMART on FHIR launch context loading the patient encounter, the model output rendered in an in-EHR review-and-edit UX. For a coding copilot — the encounter documentation alongside the suggested codes with citation links. For a triage copilot — the patient presentation with the suggested disposition and rationale.
The demo doesn’t have to be production-ready. It has to be evocative enough that a clinician reviewing it can recognize the workflow they would actually use. Demo videos shot in this format are the artifact most often cited by buyers when they make the production-investment decision after the POC.
Integration touchpoints. Code that simulates the production integration — calling the FHIR API, reading the encounter context, rendering output through the channel the user would actually use. For most POCs, the integration is mocked or read-only — the POC doesn’t write back to the production EHR — but the integration shape is real. This artifact is what proves to the executive review that the production-deployment path is technically clear.
Updated eval report. The eval metrics packaged for non-technical review — what the model achieves, against what gold standard, with what residual error modes, and with what production-deployment implications. The report includes the clinician reviewer’s quantitative scores, error-mode categorization, and a fairness assessment across subgroups.
Decision gate. End of week 5: demo experience runs end-to-end; integration touchpoints exercised; eval report reviewed by the project owner. The POC is now ready for the week 6 production-readiness assessment.
Week 6: Final Artifact, Validation Report, and Production-Readiness Assessment
The final week packages the POC for review and produces the production-readiness assessment. The week 6 deliverables are (1) the final POC artifact with documentation, (2) the validation report covering technical, clinical, and economic readiness, (3) the production-readiness gap assessment, and (4) the executive review meeting.
Final POC artifact. Working code, deployable in a development environment, with clear instructions for the next team to operate it. README, environment setup, dependency manifest, eval-harness invocation, demo-environment configuration. The artifact is reproducible — another team can pick it up and run it.
Validation report. The 8–15 page deliverable covering:
- The use case (problem, user, outcome)
- Technical architecture (data flow, model selection, infrastructure, compliance posture)
- Eval methodology (metrics, gold standard, test set construction)
- Eval results (numbers, calibration, subgroup performance, error modes)
- Clinical reviewer signoff (quantitative ratings, qualitative observations, residual concerns)
- Economic case (unit economics, ROI projection, sensitivity analysis)
- Production-readiness gap (what’s needed to move from POC to production, including engineering, compliance, integration, and validation work)
- Recommendation (go to production / iterate further / don’t proceed)
This report is what gets read by people who didn’t participate in the POC. It has to communicate a credible story to a hospital board, a healthtech investor, or an executive review committee — without technical preparation.
Production-readiness gap assessment. The explicit list of what moves the POC into production. For most healthcare AI use cases the production gap includes:
- Production-grade compliance architecture (BAA paper trail with every vendor, audit log meeting §164.312(b), retention/deletion policy across the AI memory surface, Security Risk Analysis under §164.308(a)(1)(ii)(A))
- Production EHR integration (SMART on FHIR launch context, FHIR R4 read and write-back, certification through App Orchard / Cerner Code Console / athenaOne marketplace / Allscripts ADP)
- Production model serving (inference gateway, model versioning, drift monitoring, on-call coverage)
- Production validation (full eval against production-scale test set, subgroup performance verified, calibration confirmed, FDA SaMD pathway scoping if applicable)
- Production UX (clinician override workflow, audit logging of accept/edit/reject, content-safety filtering, error handling)
The production gap is typically 4–8x the POC engineering investment, with substantial new compliance and integration scope. The 12-week MVP and the 24-week production deployment are the standard next steps.
Executive review meeting. The 60-minute meeting with the project owner and stakeholders covering the validation report findings, the production-readiness gap, and the production decision (go / iterate / stop). POCs that produced the four artifacts above and ran the gates rigorously typically convert to a production engagement at this meeting. POCs that skipped artifacts or skipped gates produce executive reviews that drag, get rescheduled, or end without a clear decision.
Common POC Failure Modes
The five patterns that produce 6-week POCs that fail to convert.
Failure 1 — No named clinical reviewer. The POC produces engineering output that no clinician has rated. The “validation” reduces to engineer-rated quality, which doesn’t survive executive review. Resolution: identify and engage the clinical reviewer in the scoping conversation. Pay them if necessary. Their signoff is the single most important artifact.
Failure 2 — Synthetic data only. The POC ran on synthetic data because real data access took longer than the engagement allowed. Eval metrics on synthetic data don’t predict performance on real data. Resolution: data access is confirmed in week 1; if it’s not accessible by end of week 2, the engagement pauses until it is. Don’t push forward on synthetic data alone.
Failure 3 — Eval methodology gaps. The POC produces accuracy claims without rigorous eval methodology — no held-out test set, no gold-standard labels, no calibration check, no subgroup analysis. The accuracy claim doesn’t survive review. Resolution: eval harness is built in week 2, before the first model run, and stays the team’s primary measurement instrument throughout.
Failure 4 — Integration story missing. The POC produces a working model but no demonstration of how it integrates with the production system. Executive review can’t visualize the deployment. Resolution: integration touchpoints are part of the week 5 deliverable; the demo experience renders output in the actual user workflow.
Failure 5 — Production-readiness gap not assessed. The POC ships without an explicit production-readiness gap. The executive review wants to know “what’s the next step” and the team can’t answer specifically. The decision drags. Resolution: production-readiness gap assessment is a non-optional week 6 deliverable; it forces the team to plan the next 12 weeks before the POC closes.
The fix in every case is the same: every gate is non-negotiable, every artifact has a defined acceptance criterion, every week produces something the project owner can review independently.
What Comes After the POC
The successful POC produces three possible next-step decisions.
Decision 1 — Go to production. The POC validated technical, clinical, and economic readiness. The next step is the 12-week MVP that produces a production-deployable artifact with full compliance architecture, production EHR integration, and production-grade eval. Taction’s productized progression is Discovery Sprint ($45K, 6 weeks) → MVP Sprint ($95K cumulative, 8 weeks) → Pilot-Ready Sprint ($145K cumulative, 12 weeks). The POC fits inside the Discovery Sprint; the production path proceeds through the MVP and Pilot-Ready Sprints. The full progression is covered on our healthcare engineering practice.
Decision 2 — Iterate further. The POC was promising but not yet conclusive — accuracy was below target but trajectory was positive, or one error mode needs more work, or the regulatory posture needs clarification. The next step is a 4–6 week extended POC focused on the specific gap. Most POCs that need a second iteration pass through it successfully on the second pass.
Decision 3 — Don’t proceed. The POC validated that the use case isn’t viable in its current form — the data access was harder than expected, the accuracy ceiling is too low, the regulatory pathway is too narrow, the unit economics don’t work. This is a successful POC outcome — the organization saved 4–8x the production cost by validating the constraint at the POC stage. POCs that surface “don’t proceed” findings within 6 weeks are far more valuable than production engagements that surface them after $1M+ of investment.
A well-run POC produces a defensible answer regardless of which of the three decisions emerges. The structure that makes the answer defensible is the same structure that produces the POC: scoped use case, named clinical reviewer, rigorous eval, real data, integration shape, executive-readable validation report, explicit production-readiness gap.
Closing
The 6-week healthcare AI POC is a structured engineering engagement, not a science project. The structure is non-negotiable. The artifacts are well-defined. The decision gates either pass or trigger a structured response. POCs that follow the structure ship in 6 weeks with executive-defensible outputs. POCs that skip the structure ship in 12+ weeks with outputs no one trusts.
If you are scoping a healthcare AI POC and want a partner who runs the format with productized rigor, book a 60-minute scoping call. Taction Software’s $45K Discovery Sprint is the productized form of this 6-week format — with the architectural foundation we ship as default, the eval harness built into the engagement, the clinical reviewer engagement structure built in, and the production-readiness gap assessment as the final deliverable. Every Discovery Sprint we ship comes with a 100% satisfaction guarantee on the work — buyers who don’t accept the deliverables get the engagement fee refunded. Our verified case studies cover the production deployments these POCs converted into.
For deeper context on healthcare MVP development beyond the POC stage, our healthcare MVP development practice covers the next steps. For the engineering scope behind the engagement, see our healthcare engineering team and our hospital and health-system practice for the operational context. For an estimate against your specific use case, see the healthcare engineering cost calculator.